Ticagrelor en post-angioplastie

Abstract

Cardiovascular diseases are the leading cause of death worldwide, with 17.5 million deaths in 2012. Optimal therapeutic management makes it possible to greatly reduce this morbiditymortality. Oral dual antiplatelet therapy consisting of acetylsalicylic acid (ASA) and Ticagrelor (BRILLIQUE®) is recommended for the treatment of patients with acute coronary syndromes (ACS), who have undergone a percutaneous coronary intervention (PCI). It requires special monitoring due to the side effects mainly haemorrhages and dyspnea, also the risk of ineffective action on platelet function. Our work aimed to evaluate the efficacy and tolerance of Ticagrélor following an angioplasty as a primary objective, another secondary is to know the epidemiological profile of the population that is benefited from the therapeutic strategy studied. A retrospective observational study was conducted between 01.01.2018 and 12.12.2019. The data were collected from the medical records of 45 patients, prescribed with Ticagrelor in combination with aspirin following an angioplasty, hospitalized at the cardiology department of the CHU of SETIF, using a data collection sheet. Minor bleeding occurred among 6.6% of patients and no major bleeding case was reported. For dyspnea, three cases (6.6%) occurred where discontinuation of treatment was necessary for one patient. Ischemia occurred among 15.6% of the patients, also one death from ischemic heart disease has been registered. Brilinta has proved a good tolerance and efficacy based on the results of the clinical evaluation of this population over a period of one to four weeks of treatment, which are in agreement with those in the literature.